Regimens for chronic infection with genotypes 4–6 HCV in people who are treatment-naive

The first-line DAA regimens that are approved for the treatment of Gt 4–6 HCV include sofosbuvir plus velpatasvir (see Sofosbuvir plus velpatasvir) [34] and glecaprevir plus pibrentasvir (see Glecaprevir plus pibrentasvir). [36] The combination of elbasvir plus grazoprevir is also PBS-listed for the treatment of Gt 4 HCV (Table 3). SVR rates ≥ 95% were observed in Phase III studies using the recommended treatment regimens. [36],[38-40],[59]